All Stories

  1. Towards implantable supercapacitors with high longevity
  2. Targeted Delivery of Microneurotrophin BNN27 via Biomaterial Grafts Protects Retinal Ganglion Cells After Optic Nerve Injury
  3. Computational Methods for Cancer Neoantigen Prediction
  4. Deciphering the Tumor Microenvironment Composition Using Bulk Transcriptomics: A Guide to Recent Advances and Open Challenges
  5. Using Epigenetic Data to Deconvolute Immune Cells in Cancer from Blood Samples
  6. Intepirdine Derivatives Possessing Dual 5HT6 Antagonism / HDAC6 Inhibitory Activity
  7. Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling
  8. CAR Exosome-Based Therapeutics
  9. An expert consensus statement on biomarkers of ageing for use in intervention studies
  10. AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors
  11. Profiling Plasma Extracellular Vesicle Metabotypes and miRNAs: An Unobserved Clue for Predicting Relapse in Patients with Early-Stage NSCLC
  12. Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for OMICS: A Journal of Integrative Biology
  13. Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimer’s disease
  14. Natural Compounds for Bone Remodeling: A Computational and Experimental Approach Targeting Bone Metabolism-Related Proteins
  15. Clinical implementation of preemptive pharmacogenomics in psychiatry
  16. Data-Driven Drug Repurposing in Diabetes Mellitus through an Enhanced Knowledge Graph
  17. Cloudscreen: A “one-stop-shop” Platform for Drug Repurposing
  18. A quest for the stereo-electronic requirements for selective agonism for the neurotrophin receptors TrkA and TrkB in 17-spirocyclic-dehydroepiandrosterone derivatives
  19. A Robust Machine Learning Framework Built Upon Molecular Representations Predicts CYP450 Inhibition: Toward Precision in Drug Repurposing
  20. Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimer’s Disease.
  21. Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimer’s Disease
  22. Bioenergetic Profiling in Glioblastoma Multiforme Patients with Different Clinical Outcomes
  23. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
  24. Development of a multigram synthesis of the bradykinin receptor 2 agonist FR‐190997 and analogs thereof
  25. Development and Comparative In Vitro and In Vivo Study of BNN27 Mucoadhesive Liposomes and Nanoemulsions for Nose-to-Brain Delivery
  26. CAR Exosome-Based Therapeutics
  27. Pharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean
  28. Untargeted Metabolomics for Disease-Specific Signatures
  29. Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications
  30. Diagnostic and Therapeutic Challenges in a Patient with Ureteral Metastases from a Triple Negative Breast Cancer
  31. A 3-miRNA Signature Enables Risk Stratification in Glioblastoma Multiforme Patients with Different Clinical Outcomes
  32. Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries
  33. The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review
  34. ENT-A010, a Novel Steroid Derivative, Displays Neuroprotective Functions and Modulates Microglial Responses
  35. Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity
  36. Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine
  37. Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology
  38. Insights into intrauterine growth restriction based on maternal and umbilical cord blood metabolomics
  39. Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts
  40. The Metabolomic Status of the Differentiating Myeloid Lineage in MDS with Low and High Bone Marrow Blast Counts
  41. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe “PREPARE” study
  42. The role of microRNAs in gliomas – Therapeutic implications
  43. Documentation of clinically relevant genomic biomarker allele frequencies in the next‐generation FINDbase worldwide database
  44. Multiomics Analysis Coupled with Text Mining Identify Novel Biomarker Candidates for Recurrent Cardiovascular Events
  45. Challenges in identifying large germline structural variants for clinical use by long read sequencing
  46. VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
  47. 4th ESPT Conference: Pharmacogenomics and Personalized Medicine – Research Progress and Clinical Implementation
  48. Corrigendum
  49. Pharmacomicrobiomics informs clinical pharmacogenomics
  50. Genomic Variants in Members of the Krüppel-Like Factor Gene Family are Associated with Disease Severity and Hydroxyurea Treatment Efficacy in β-Hemoglobinopathies Patients
  51. A Noninvasive Ocular (Tear) Sampling Method for Genetic Ascertainment of Transgenic Mice and Research Ethics Innovation
  52. Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow
  53. New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis
  54. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention
  55. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study
  56. Implementation of Genomic Medicine
  57. Autophagy in Myelodysplastic Syndromes: The Role of HIF-1a/REDD1 Molecular Pathway
  58. How far have we come with contextual data integration in drug discovery?
  59. Variants in TPMT, ITPA, ABCC4 And ABCB1 Genes as Predictors of 6-Mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia
  60. Can VEGFA and ICAM1 polymorphisms predict response to bevacizumab?
  61. An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients
  62. The New Age of -omics in Urothelial Cancer – Re-wording Its Diagnosis and Treatment
  63. Recent trends on the role of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment
  64. Searching for Clinically Relevant Biomarkers in Geriatric Oncology
  65. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis
  66. Proteomics and Metabolomics Data Analysis for Translational Medicine
  67. A Review of Tools to Automatically Infer Chromosomal Positions From dbSNP and HGVS Genetic Variants
  68. Economic Evaluation and Cost-Effectiveness Analysis of Genomic Medicine Interventions in Developing and Emerging Countries
  69. Human Genomic Databases in Translational Medicine
  70. Translating Genomic Information to Rationalize Drug Use
  71. The Genomic Medicine Alliance: A Global Effort to Facilitate the Introduction of Genomics into Healthcare in Developing Nations
  72. Advancing Global Precision Medicine: An Overview of Genomic Testing and Counseling Services in Malaysia
  73. Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients
  74. Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New “Fast-Second Winner” Strategy
  75. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients
  76. Cancer Genomics and Public Health
  77. Sensitive Monogenic Noninvasive Prenatal Diagnosis by Targeted Haplotyping
  78. Exploring public genomics data for population pharmacogenomics
  79. Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation
  80. Key Pharmacogenomic Considerations for Sickle Cell Disease Patients
  81. Editorial: (Pharmaco)Metabolomics in Drug Discovery and Individualisation of Treatment
  82. Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
  83. Genomic Medicine in Developing Countries and Resource-Limited Environments
  84. Genomic Databases
  85. Perspectives for Future DNA Sequencing Techniques and Applications
  86. Cancer Genomics and Public Health
  87. Application of the DruGeVar Database in Cancer Genomics and Pharmacogenomics
  88. Exosomes: A Cancer Theranostics Road Map
  89. Pharmacogenomics in Clinical Care and Drug Discovery
  90. Low- and Medium-Throughput Variant Detection Methods
  91. Pharmacogenomics education and research at the Department of Pharmacy, University of Patras, Greece
  92. Correlation of SIN3A genomic variants with β-hemoglobinopathies disease severity and hydroxyurea treatment efficacy
  93. Pharmacometabolomics Informs Viromics toward Precision Medicine
  94. Novel genetic risk variants for pediatric celiac disease
  95. Expanded national database collection and data coverage in the FINDbase worldwide database for clinically relevant genomic variation allele frequencies
  96. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
  97. ePGA: A Web-Based Information System for Translational Pharmacogenomics
  98. Development and validation of a UHPLC-UV method for the determination of a prostate secretory protein 94-derived synthetic peptide (PCK3145) in human plasma and assessment of its stability in human plasma
  99. Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease
  100. Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients
  101. Nutrigenomics 2.0: The Need for Ongoing andIndependentEvaluation and Synthesis of Commercial Nutrigenomics Tests' Scientific Knowledge Base for Responsible Innovation
  102. Allele and genotype frequencies of the two single nucleotide polymorphisms in the VKORC1 gene that are most important for warfarin treatment among Emiratis
  103. Computational approaches in target identification and drug discovery
  104. Pharmacometabolomics: Applications and Challenges
  105. Functional Analysis of anAγ-Globin Gene Promoter Variant (HBG1: g.-225_-222delAGCA) Underlines Its Role in Increasing Fetal Hemoglobin Levels Under Erythropoietic Stress
  106. Enabling pharmacogenomic services: Informatics and computational discovery aspects
  107. Identification of a novel homozygous SPG7 mutation by whole exome sequencing in a Greek family with a complicated form of hereditary spastic paraplegia
  108. TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner
  109. Drug-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via Pharmacogenomics
  110. As solid scientific evidence is lacking, available nutrigenomics tests cannot be recommended
  111. The Implications of Metabotypes for Rationalizing Therapeutics in Infants and Children
  112. Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach
  113. Whole genome sequencing in pharmacogenomics
  114. Nutrigenomics: A controversy
  115. Pharmacogenomics for Haemoglobinopathies Therapeutics
  116. Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
  117. Deciphering next-generation pharmacogenomics: an information technology perspective
  118. Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion
  119. Personalized pharmacogenomics profiling using whole-genome sequencing
  120. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients
  121. Assessment of the Pharmacogenomics Educational Environment in Southeast Europe
  122. DruGeVar: An Online Resource Triangulating Drugs with Genes and Genomic Biomarkers for Clinical Pharmacogenomics
  123. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice
  124. Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: Enhanced enzymatic stability and biological properties
  125. 1077 Ovarian Malignant Ascites-derived Lymphocytes Stimulated With Prothymosin Alpha or Its Immunoactive Decapeptide Lyse Autologous Tumor Cells in Vitro and Retard Tumor Growth in SCID Mice
  126. Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry
  127. Evaluation of a Stable Gonadotropin-Releasing Hormone Analog in Mice for the Treatment of Endocrine Disorders and Prostate Cancer
  128. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis
  129. Simultaneous Absolute Quantification of the Glucose-Dependent Insulinotropic Polypeptides GIP1−42and GIP3−42in Mouse Plasma by LC/ESI-MS/MS: Preclinical Evaluation of DP-IV Inhibitors
  130. In vivoevaluation andin vitrometabolism of leuprolide in mice-mass spectrometry-based biomarker measurement for efficacy and toxicity
  131. Evaluation of gonadotropin-releasing hormone analogues in mice – pharmacokinetic studies and biomarker based efficacy by mass spetrometry